Drug intelligence / Profile preview

IFX002

Development stage: Preclinical
Lead developer: InflaRx
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Injectable

Overview

**IFX002** is a highly potent monoclonal antibody that specifically targets and inhibits complement C5a, a key amplifier of inflammatory responses. Developed by InflaRx, it is designed for subcutaneous or injectable administration to treat sub-acute and acute inflammatory conditions as well as chronic inflammatory indications. By blocking C5a-directed inflammatory signaling without affecting the membrane attack complex (C5b-9), IFX002 aims to control excessive inflammation while preserving essential innate immune defenses.[1][3][5]

Targets

Complement component C5a

Beyond the preview

Go deeper on IFX002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IFX002.

Explore the full profile